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Renoprotection with vitamin D: 
Specific for diabetic nephropathy?
G Klaus1
Zhang and co-workers report on the renoprotective role of the 
vitamin D receptor (VDR) in diabetic nephropathy using the method of 
streptozotocin-induced hyperglycemia in wild-type and VDR–/– mice. 
Also, experiments with cultured mesangial cells and podocytes confirm 
the effect of the active vitamin D metabolite 1,25(OH)2D3 on inhibition 
of the renin–angiotensin system (RAS) in vitro. The authors conclude 
that the higher activation of the intrarenal RAS is the key factor to 
induce more severe diabetic nephropathy in VDR–/– mice.
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Vitamin D is hydroxylated in the liver 
by 25-hydroxylase to 25-(OH) vitamin 
D. A second, subsequent hydroxylation 
in the proximal renal tubule by 1α-
hydroxylase is required to form the active 
metabolite 1,25(OH)2D3. The binding of 
1,25(OH)2D3 to its nuclear vitamin D 
receptor (VDR) leads to VDR activation 
and heterodimerization with the retinoid 
X receptor (RXR) and other cofactors, 
to form the VDR–RXR complex, which 
binds to the vitamin D response element 
of target genes to regulate gene transcrip-
tion. The VDR has been found in many 
tissues—not only in the classical target 
organs, intestine, kidney, and bone, but 
also in diﬀerent cell types, including the 
immune system; this suggests a role of 
vitamin D well beyond regulation of cal-
cium. The vitamin D system is involved 
in regulating the immune system, cell 
growth, and diﬀerentiation (reviewed by 
Holick1). For example, vitamin D supple-
mentation in infancy is associated with 
a reduced risk of development of type 1 
diabetes. Recently, renoprotective actions 
of active vitamin D metabolites were 
reported in an experimental setting of 
glomerulonephritis as well as in human 
chronic renal disease.
Role of vitamin D and the (intrarenal) 
renin–angiotensin system in diabetic 
and nondiabetic nephropathy
VDR–/– mice express elevated angiotensin 
II plasma levels due to increased intra-
renal renin activity.2 Increased activity 
of the renin–angiotensin system (RAS) 
could also be demonstrated in vitamin D-
deﬁcient wild-type mice, whereas treat-
ment with 1,25(OH)2D3 reduced renin 
activity. These studies demonstrate that 
the vitamin D system acts as a negative 
regulator of the intrarenal RAS by sup-
pressing renin activity independently.2 
The reduced activity of the intrarenal RAS 
is considered to be an important factor in 
the renoprotective role of active vitamin D 
metabolites in experimental and human 
chronic kidney disease. Hyperglycemia 
induces intrarenal renin production and 
downregulates VDR and 1α-hydroxylase 
in proximal tubular cells. The combina-
tion of hyperglycemia and absence of the 
VDR is therefore expected to result in a 
further increase of the intrarenal RAS 
activity, as is elegantly demonstrated in 
vivo and in vitro in the study by Zhang 
et al.3 (this issue). However, increased 
renin leads to higher systemic blood 
pressure, and, in fact, this was reported 
in the nondiabetic VDR–/– mouse.2 This 
might even be more pronounced in 
VDR–/– mice with diabetes, resulting in 
additive disturbances of the systemic and 
renal vasculature, promoting glomerular 
changes, proteinuria, and interstitial 
ﬁbrosis. However, a trend toward reduced 
blood pressure in the streptozotocin-
treated mice in the presence of signiﬁ-
cant hyperglycemia was reported.4 Blood 
pressure in the diabetic VDR–/– and wild-
type mice was not reported in the study 
by Zhang et al.3
With streptozotocin-induced diabetes 
in the mouse, proteinuria is observed 
after approximately 5 weeks. Because 
at this early time the most prominent 
histologic marker of diabetic neph-
ropathy is glomerular hypertrophy, it 
seems likely that hemodynamic eﬀects 
contribute to the development of early 
albuminuria, which is superimposed on 
the proteinuria observed in the nondia-
betic VDR–/– mouse. This assumption 
is in line with the clinical observation 
of elevated blood pressure in a sub-
stantial number of young patients with 
type 1 diabetes even in the absence of 
microalbuminuria.5
Activation of the intrarenal renin–
angiotensin system and progression of 
chronic kidney disease?
Hyperglycemia itself induces proteinu-
ria, and this is augmented by lack of 
activity of the vitamin D system. Pro-
teinuria results in a decline of tubular 
megalin expression, resulting in lower 
endocytosis. This leads to decreased 
25(OH)D3 reabsorption and increased 
proteinuria. Endogenous 1,25(OH)2D3 
counterbalances the decline in mega-
lin abundance and reduced 25(OH)D3 
uptake.6 Hyperglycemia increases abun-
dance and translocalization of protein 
kinase Cα (PKCα) in glomerular cells 
and, most prominently, in capillaries. 
Several effects of hyperglycemia are 
mediated by PKC activation, such as 
increased endothelial-cell permeabil-
ity and stimulated expression of matrix 
proteins and metalloproteinases.7 
Angiotensin II is also known to stimu-
late PKC. An important eﬀect of PKC 
stimulation is an increase in transform-
ing growth factor-β (TGF-β), resulting 
in increased capillary permeability and 
ﬁbrogenic activity. In addition, TGF-β 
is involved in myoﬁbroblast activation 
of interstitial fibroblasts and tubular 
epithelial-to-mesenchymal transition,8 
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Figure 1 | Proposed effects of active vitamin D metabolites on development of diabetic 
nephropathy. Hyperglycemia stimulates the intrarenal renin–angiotensin system (RAS) and 
formation of transforming growth factor-β (TGF-β) and other cytokines as well as proteinuria. 
TGF-β induces tubular epithelial-to-mesenchymal transition and stimulation of profibrotic 
signals. Increased activity of the RAS induces hemodynamic changes in the glomerulus followed 
by increased glomerular volume, mesangial proliferation, and podocyte injury. Active vitamin 
D metabolites bind to the vitamin D receptor (VDR) and inhibit stimulation of the RAS as well 
as podocyte and mesangial-cell proliferation. In addition, active vitamin D counterbalances 
fibrogenesis by inhibiting TGF-β indirectly via the activation of hepatocyte growth factor. In 
consequence, active vitamin D metabolites reduce glomerulosclerosis and tubulointerstitial fibrosis.
an important event in the generation of 
α-smooth muscle actin-positive matrix-
producing cells in the kidney, which pro-
motes a ﬁbrogenic process. Active vitamin 
D metabolites not only reduce intrarenal 
RAS activation but also suppress TGF-β 
activation indirectly via stimulation of the 
hepatocyte growth factor. Therefore, it is 
not surprising that nondiabetic VDR–/– 
mice show increased proteinuria as com-
pared with their wild-type littermates. 
The same mechanism can be proposed 
for the more pronounced proteinuria 
induced by hyperglycemia in the VDR–/– 
mouse compared with the wild-type one, 
indicating more severe diabetic neph-
ropathy. However, the amount of pro-
teinuria that is indicative of glomerular 
disease in the mouse model has not been 
ﬁrmly established.4 Reduced proteinuria 
with administration of 1,25(OH)2D3 or 
its analogues was described in several 
experimental models of chronic kidney 
disease. In ﬁve-sixths subtotally nephrec-
tomized rats, 1,25(OH)2D3 signiﬁcantly 
reduced proteinuria.9 Furthermore, the 
1,25(OH)2D3 analogue 22-oxa-calcitriol 
not only reduced protein excretion but 
also inhibited glomerular hypertrophy 
and glomerulosclerosis (see below). In 
addition, there is clinical evidence that 
active vitamin D metabolites have anti-
proteinuric effects in human chronic 
kidney disease stages 3 and 4. In double-
blind, placebo-controlled studies, parical-
citol reduced proteinuria in about 50% of 
the patients, whereas in the placebo group 
this was observed in only 25%.10
Effect of vitamin D and hyperglycemia 
on mesangial cells and on podocytes
Human diabetic nephropathy is histo-
logically characterized by diﬀuse thick-
ening of the glomerular basal membrane 
between the endothelium and the podo-
cyte and by mesangial expansion. With 
progressing time, arteriolar hyalinosis 
and tubulointerstitial ﬁbrosis develop. 
Mesangial cells express VDR. Treatment 
with 1,25(OH)2D3 inhibited mesangial-
cell proliferation in vivo in experimen-
tal anti-Thy-1 glomerulonephritis.11 
Furthermore, reduced albuminuria and 
decreased glomerulosclerosis as well as 
reduced expression of ﬁbrogenic markers 
were reported in this study. In the diabetic 
mouse model, the glomerular hypertro-
phy is followed by mesangial proliferation 
and mesangial sclerosis. In the latter two 
events, TGF-β plays a signiﬁcant role in 
the pathogenesis.
In diabetic nephropathy, the initial 
glomerular alterations also affect the 
podocyte as an important cell for disease 
progression, especially with respect to 
development of proteinuria. In subtotally 
nephrectomized rats, podocyte hypertro-
phy could be prevented by concomitant 
1,25(OH)2D3.
12 Also, markers of podo-
cyte integrity as well as podocyte number 
could be preserved with 1,25(OH)2D3. In 
the study by Zhang et al.,3 podocin levels 
were measured to assess podocyte integ-
rity. But podocin expression was not dif-
ferent in diabetic VDR–/– mice compared 
with wild-type diabetic mice. On one 
hand, this indicates the absence of toxicity 
of the low-dose streptozotocin protocol 
used; on the other hand, the podocytes 
were not significantly affected by the 
hyperglycemia-induced hemodynamic or 
vitamin D-depleted eﬀects. In view of the 
described increased glomerulosclerosis 
index in the diabetic VDR–/– mouse, this 
is surprising, but it may be explained by 
the relative resistance to the development 
of glomerulosclerosis and renal failure4 in 
the mouse strain used.
Summary
Experimental and clinical evidence is 
accumulating that indicates a renopro-
tective role of the vitamin D system in 
chronic renal disease, including diabetic 
nephropathy (Figure 1). Both hyperglyc-
emia and the absence of the vitamin D-
dependent signals stimulate the intrarenal 
activity of the RAS with elevated renin and 
angiotensin II levels. An important com-
mon pathway for the synergistic eﬀect of 
hyperglycemia and inactivity of the vita-
min D system is stimulation of TGF-β. 
In turn, TGF-β induces proﬁbrotic events 
that result in interstitial ﬁbrosis. Active 
vitamin D metabolites inhibit the activa-
tion of the RAS as well as the induction of 
the ﬁbrotic cascade. Diabetic nephropa-
thy is also characterized by glomerular 
changes, that is, glomerular tuft expan-
sion and glomerulosclerosis. Experi-
mental models of glomerulonephritis or 
subtotal nephrectomy as well as the study 
by Zhang et al.3 suggest reduced podocyte 
injury and less mesangial proliferation 
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with the administration of active vitamin 
D metabolites. Reduced glomerular and 
tubulointerstitial alterations are accom-
panied by reduced proteinuria in experi-
mental diabetic nephropathy and other 
experimental kidney disease. Reduced 
proteinuria with administration of active 
vitamin D was also conﬁrmed in human 
subjects with chronic kidney disease. 
The reported increased susceptibility of 
the kidneys of VDR–/– mice to hypergly-
cemia might hold not only for diabetic 
nephropathy, but also for other chronic 
kidney diseases. These ﬁndings all sug-
gest that vitamin D deﬁciency should 
be avoided in diabetic and nondiabetic 
chronic kidney disease. However, the 
eﬀect of (low) doses of active vitamin D 
metabolites on development of diabetic 
nephropathy in patients with diabetes 
should be evaluated in prospective ran-
domized clinical trials.
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Preservation of residual renal 
function in peritoneal dialysis 
patients: Still a dream?
F Locatelli1 and V La Milia1
The results of the randomized trial by Fan et al. suggest that 
‘biocompatible’ peritoneal dialysis solutions have no major advantage 
over standard solutions in peritoneal dialysis patients in relation to 
residual renal function (RRF) and technique survival. The possible effect 
of more biocompatible peritoneal dialysis solutions on RRF should be 
tested in patients starting peritoneal dialysis programs with relatively 
well-preserved RRF. When RRF is already very poor, it is very unlikely that 
a more biocompatible peritoneal dialysis solution can preserve highly 
damaged and sclerotic kidneys. 
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Chronic kidney disease is often character-
ized by a progressive loss of renal function, 
and the start of dialysis further decreases 
residual renal function (RRF). This is of 
particular concern because RRF and diure-
sis are known to be major determinants of 
patient survival and, at least in the case of 
peritoneal dialysis, technique survival. It is 
therefore not surprising that nephrologists 
are interested in evidence-based data con-
cerning the best strategies for preserving 
renal function in patients on dialysis.
The results of observational studies 
have shown that high-ﬂux biocompatible 
membranes not only reduce serum β2-
microglobulin levels more eﬃciently than 
low-ﬂux bioincompatible membranes but 
also lead to a lower incidence of dialysis-
related amyloidosis and improve lipid 
profiles, peripheral nerve conductivity, 
and the susceptibility to infection.1 Even 
more important for the purposes of this 
Commentary is that the use of high-ﬂux 
biocompatible membranes had been asso-
ciated with a slower decrease in RRF in 
previously reported cohort studies.2
Cohort studies may have the advan-
tage of being more representative of all 
patients in real everyday clinical prac-
tice, but they are limited by the fact that 
controlling for confounding factors is 
restricted to what is already known and, 
although they can reveal associations, 
they can never prove causation. Further-
more, their positive ﬁndings are often 
contradicted by the surprising results of 
randomized controlled trials.
One clear example of this is the Hemo-
dialysis (HEMO) Study,3 which not only 
failed to conﬁrm previous observational 
data indicating that more dialysis is bet-
ter but, even more importantly, did not 
support the view that high-ﬂux biocompat-
ible dialysis is better than low-ﬂux dialysis. 
However, the preliminary results of the 
Membrane Permeability Outcome study4 
presented at the European Renal Asso-
ciation–European Dialysis and Transplant 
Association Congress in Barcelona in June 
seem to challenge the HEMO ﬁndings.
As preservation of RRF is associ-
ated with improved patient survival, 
any approach that may accomplish it is 
welcome not only in the early stages of 
chronic kidney disease (in an attempt to 
prevent the need for dialysis), but also in 
patients with stage 5 chronic kidney dis-
ease who are already on dialysis.
